Netarsudil

Netarsudil
Clinical data
Trade names	Rhopressa
Other names	AR-11324
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name [4-[(2S)-3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;
CAS Number	1254032-66-0;
PubChem CID	66599893;
DrugBank	DB13931;
UNII	W6I5QDT7QI;
KEGG	D11030;
ECHA InfoCard	100.251.524
Chemical and physical data
Formula	C28H27N3O3
Molar mass	453.542 g·mol−1
	InChI InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1; Key:OURRXQUGYQRVML-AREMUKBSSA-N;

Netarsudil (trade name Rhopressa) is a drug for the treatment of glaucoma. In the United States in 2017 the Food and Drug Administration approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1] It targets the trabecular meshwork directly.[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.